• Journal of Distribution Science
• /
• v.20 no.7
• /
• pp.57-64
• /
• 2022

Purpose: The government of India has initiated the Covid-19 Vaccination drive from early January 2021. Vaccination is identified to be best option to protect the people across the globe. However, owing to fast wide spread of the Covid-19, the Vaccine Distribution is a major challenge owing various issues like temperature control, infrastructure, hesitancy, geographical diversity, and other critical factors. Various research is carried out globally to understand and study the Vaccine Distribution issues based on the respective country issues and factors. Research Design, Data, and Methodology: This research paper attempts to explore prominent factors that could be taken up on priority for better and effective vaccination program. The study tries to rank various factors and sub-factors affecting vaccine distribution in India. AHP methodology based on feedback from 22 experts from the Vaccine industry has been deployed to get the desired results. Result: The results show that factors vaccine approval process, geographical prioritization, power supply, infrastructure maintenance costs for vaccine storage, and vaccine pricing are the prominent factors of effective vaccination in the country. Conclusion: The role and need for district-level health officers towards vaccine storage has been brought forward. A long-term effective vaccination policy is needed for optimum vaccine distribution.

• Proceedings of the PSK Conference
• /
• 2003.04a
• /
• pp.295.2-295.2
• /
• 2003

Lipid nanodispersion (LN) composed of biocompatible lipids and surfactants is an alternative parenteral drug delivery system especially for lipophilic drugs. It has been studied for versatile applications such as oral, parenteral, topical, ocular, vaccine, and peptide drug delivery. The purpose of this study was to produce a novel LN system for intravenous injection using the high pressure homogenization. (omitted)

• Journal of Appropriate Technology
• /
• v.7 no.1
• /
• pp.26-32
• /
• 2021

In the process of vaccine delivery and vaccination, temperature is mostly controlled by an insulated containers containing ice. Moreover, amount of wasted vaccine is significant because the temperature of the vaccine is not properly controlled. A core challenge of vaccination is temperature data monitoring, since it is critical for managing and operating strategical vaccination by health organizations. In this research, a real-time monitoring vaccine carrier system was developed. Temperature, location, and power consumption data of the vaccine carrier were monitored and working performances of the vaccine carrier were tested in both Korea and Tanzania (Arusha and Kilimanjaro regions). For both places, Short Message Service (SMS) communication method was used to send information of the carrier's status. As a result, the monitoring system was able to transmit and receive real-time data of the vaccine carrier status while the vaccine carrier was tested. The vaccine status data can be accessed from any location through the cloud server and web-based user interface.

• Journal of Microbiology and Biotechnology
• /
• v.18 no.3
• /
• pp.591-599
• /
• 2008

A murine model immunized by systemic and mucosal delivery of plasmid DNA vaccine expressing glycoprotein B (pCIgB) of pseudorabies virus (PrV) was used to evaluate both the nature of the induced immunity and protection against a virulent virus. With regard to systemic delivery, the intramuscular (i.m.) immunization with pCIgB induced strong PrV-specific IgG responses in serum but was inefficient in generating a mucosal IgA response. Mucosal delivery through intranasal (i.n.) immunization of pCIgB induced both systemic and mucosal immunity at the distal mucosal site. However, the levels of systemic immunity induced by i.n. immunization were less than those induced by i.m. immunization. Moreover, i.n. genetic transfer of pCIgB appeared to induce Th2-biased immunity compared with systemic delivery, as judged by the ratio of PrV-specific IgG isotypes and Th1- and Th2-type cytokines produced by stimulated T cells. Moreover, the immunity induced by i.n. immunization did not provide effective protection against i.n. challenge of a virulent PrV strain, whereas i.m. immunization produced resistance to viral infection. Therefore, although i.n. immunization was a useful route for inducing mucosal immunity at the virus entry site, i.n. immunization did not provide effective protection against the lethal infection of PrV.

• KSBB Journal
• /
• v.19 no.5
• /
• pp.341-347
• /
• 2004

Several gene delivery therapies are being developed for treatment of serum protein deficiency. EPO is one of the most promising therapeutic agent for this treatment which is currently being investigated in depth. This study has the ultimate purpose of improving the gene delivery system for an increase of red blood cell production. A plasmid DNA was constructed smaller than other plasmids for an increase in penetration into animal cells, and two genes were cloned into each vector as a co-delivery system to express erythropoietin, and interluekin-3 or thrombopoietin, which can act on erythroid cell, thus activating hematopoiesis synergically. This co-delivery system has an advantage of decreasing the labour required for industrial production of DNA vaccine. A new plasmid vector, pVAC, in size 2.9 kb, was constructed with the essential parts from PUC 19 and pSectagB, which is much smaller than other plasmid vector and is the size of 2.9 kb. Co-delivery system was constituted by cloning human erythropoietin with each of human interluekin-3 gene or human thrombopoietin gene into both pVAC and pSectagB. As a result, the transfection efficiency of pVAC was higer than that of pSectagB in vitro, and hematocrit level of the mice injected with pVAC is higher than that of other mice. And co-delivery system, made of several plasmid DNAs, was expressed in vitro.

• Journal of the korean veterinary medical association
• /
• v.30 no.12
• /
• pp.710-728
• /
• 1994

이 논문은 국내에서의 새로운 vaccine의 연구 및 개발에 참고가 되었으면 하는 뜻에서, D.T.O'Hagan저 'Novel Delivery Systems for Oral vaccines'(CRC Press, 1994) 서적 중의 소개문을 번역한 것입니다.

• Journal of Microbiology and Biotechnology
• /
• v.28 no.1
• /
• pp.122-135
• /
• 2018

Listeriolysin O (LLO), one of the most immunogenic proteins of Listeria monocytogenes and its main virulence factor, mediates bacterial escape from the phagosome of the infected cell. Thus, its expression in a nonpathogenic bacterial host may enable effective delivery of heterologous antigens to the host cell cytosol and lead to their processing predominantly through the cytosolic MHC class I presentation pathway. The aim of this project was to characterize the delivery of a model antigen, chicken egg ovalbumin (OVA), to the cytosol of dendritic cells by recombinant Bacillus subtilis vegetative cells expressing LLO. Our work indicated that LLO produced by non-sporulating vegetative bacteria was able to support OVA epitope presentation by MHC I molecules on the surface of antigen presenting cells and consequently influence OVA-specific cytotoxic T cell activation. Additionally, it was proven that the genetic context of the epitope sequence is of great importance, as only the native full-sequence OVA fused to the N-terminal fragment of LLO was sufficient for effective epitope delivery and activation of $CD8^+$ lymphocytes. These results demonstrate the necessity for further verification of the fusion antigen potency of enhancing the MHC I presentation, and they prove that LLO-producing B. subtilis may represent a novel and attractive candidate for a vaccine vector.

• IMMUNE NETWORK
• /
• v.13 no.4
• /
• pp.157-162
• /
• 2013

Application of vaccine materials through oral mucosal route confers great economical advantage in animal farming industry due to much less vaccination cost compared with that of injection-based vaccination. In particular, oral administration of recombinant protein antigen against foot-and- mouth disease virus (FMDV) is an ideal strategy because it is safe from FMDV transmission during vaccine production and can induce antigen-specific immune response in mucosal compartments, where FMDV infection has been initiated, which is hardly achievable through parenteral immunization. Given that effective delivery of vaccine materials into immune inductive sites is prerequisite for effective oral mucosal vaccination, M cell-targeting strategy is crucial in successful vaccination since M cells are main gateway for luminal antigen influx into mucosal lymphoid tissue. Here, we applied previously identified M cell-targeting ligand Co1 to VP1 of FMDV in order to test the possible oral mucosal vaccination against FMDV infection. M cell-targeting ligand Co1-conjugated VP1 interacted efficiently with M cells of Peyer's patch. In addition, oral administration of ligand-conjugated VP1 enhanced the induction of VP1-specific IgG and IgA responses in systemic and mucosal compartments, respectively, in comparison with those from oral administration of VP1 alone. In addition, the enhanced VP1-specific immune response was found to be due to antigen-specific Th2-type cytokine production. Collectively, it is suggested that the M cell-targeting strategy could be applied to develop efficient oral mucosal vaccine against FMDV infection.

• Journal of Microbiology and Biotechnology
• /
• v.16 no.2
• /
• pp.318-324
• /
• 2006

In order to develop an oral vaccine to prevent H. pylori infection, we have expressed the hpaA gene of H. pylori K51 isolated from Korean patients, encoding 29-kDa HpaA that is known to be localized on the cell surface and flagella sheath, in a live delivery vector system, Lactococcus lactis. The hpaA gene, amplified by PCR using the genomic DNA of H. pylori K51, was cloned in the pGEX-2T vector, and the DNA sequence analysis revealed that the hpaA gene of H. pylori K51 had 99.7% and 94.8% identity with individual hpaA genes of the H. pylori 26695 strain (U.K) and the J99 strain (U.S.A). A polyclonal anti-HpaA antibody was raised in rats using GST-HpaA fusion protein as the antigen. The hpaA gene was inserted in an E. coli-L. lactis-shuttle vector (pMG36e) to express in L. lactis. Western blot analysis showed that the expression level of HpaA in the L. lactis transformant remained constant from the exponential phase to the stationary phase, without extracelluar secretion. These results indicate that the HpaA of H. pylori K51 was successfully expressed in L. lactis, and suggest that the recombinant L. lactis expressing HpaA may be applicable as an oral vaccine to induce a protective immune response against H. pylori.

• Proceedings of the Korean Vacuum Society Conference
• /
• 2013.08a
• /
• pp.92.2-92.2
• /
• 2013

The design and chemical synthesis of multifunctional nanomaterials have been providing potential applications in biomedical fields such as molecular imaging and drug delivery. Recently, bio-derived and/or synthetic nanostructured materials capable of modulating the immune system have been also issues of interest in immunology-related nanomedicine fields. In this talk, the recent research results on the development of nanostructured materials for enhanced immunity would be presented. I will introduce the chemical strategy for the combination of nanostructured materials and bioactive compounds to improve both anti-cancer immunity and vaccine delivery efficiency.